Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
The Pharma Data
JUNE 28, 2021
Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Bayer’s Xofigo (radium-223 dichloride) is the first and only approved TAT.
Let's personalize your content